RNA, U6 small nuclear 182, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-182P profile across patient tissues and cancer cell-line models. RNU6-182P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNU6-182P is differentially expressed in 5, with the highest sampling consensus in BLCA. Additionally, RNU6-182P RNA expression shows 7,892 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, BLCA, and LSCC as cancer lineages where RNU6-182P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-182P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-182P survival associations across molecular data types. RNU6-182P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-182P RNA expression–survival associations across cancer types. High RNU6-182P expression shows unfavorable associations in MESO, THCA, ACC, UCS and LIHC, but favorable associations in BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RNU6-182P RNA expression.
This table summarizes RNU6-182P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-182P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-182P shows lower tumor expression in KIRP and KICH and higher tumor expression in BLCA, HNSC and BRCA. The BLCA box plot shows higher RNU6-182P RNA expression in tumor versus normal tissue (log2 FC = +0.279, t-test p = .007).
This table shows molecular features associated with RNU6-182P in patient tissues and cancer cell lines. In patient samples, RNU6-182P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
